Phase I and pharmacokinetic (PK) study of MAG-CPT (PNU 166148): a polymeric derivative of camptothecin (CPT)

Polymeric cytotoxic conjugates are being developed with the aim of preferential delivery of the anticancer agent to tumour. MAG-CPT comprises the topoisomerase I inhibitor camptothecin linked to a water-soluble polymeric backbone methacryloylglycynamide (average molecular weight 18 kDa, 10% CPT by w...

Descripción completa

Detalles Bibliográficos
Autores principales: Bissett, D, Cassidy, J, de Bono, J S, Muirhead, F, Main, M, Robson, L, Fraier, D, Magnè, M L, Pellizzoni, C, Porro, M G, Spinelli, R, Speed, W, Twelves, C
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2004
Materias:
Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2364737/
https://www.ncbi.nlm.nih.gov/pubmed/15187995
http://dx.doi.org/10.1038/sj.bjc.6601922

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2364737/
https://www.ncbi.nlm.nih.gov/pubmed/15187995
http://dx.doi.org/10.1038/sj.bjc.6601922

Ejemplares similares